Trial · NCT02780804
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat | Treatment (Entinostat) | 4 | mg/m² | ||
| Frequency of Adverse Events for Entinostat | Stratum 1 With 3 mg/m² | 5 | Participants | ||
| Frequency of Adverse Events for Entinostat | Stratum 1 With 4 mg/m² | 7 | Participants | ||
| Frequency of Adverse Events for Entinostat | PK Part With 4 mg/m² | 5 | Participants | ||
| Half-life of Entinostat | Stratum 1 With 3 mg/m² | 50.96 | Full Range 27.38 to 103.66 | Hours | |
| Half-life of Entinostat | Stratum 1 With 4 mg/m² | 46.04 | Full Range 40.51 to 81.32 | Hours | |
| Half-life of Entinostat | PK Part With 4 mg/m² | 44.23 | Full Range 29.86 to 103.74 | Hours | |
| Peak Plasma Concentration of Entinostat: C-Max | Stratum 1 With 3 mg/m² | 54.4 | Full Range 5.19 to 136.00 | ng/ml | |
| Peak Plasma Concentration of Entinostat: C-Max | Stratum 1 With 4 mg/m² | 61.5 | Full Range 14.00 to 107.00 | ng/ml | |
| Peak Plasma Concentration of Entinostat: C-Max | PK Part With 4 mg/m² | 23.8 | Full Range 19.10 to 293.00 | ng/ml | |
| Total Area Under the Plasma Concentration Curve of Entinostat: AUC | Stratum 1 With 3 mg/m² | 755 | Full Range 252 to 1320 | hr*ng/mL | |
| Total Area Under the Plasma Concentration Curve of Entinostat: AUC | Stratum 1 With 4 mg/m² | 1111 | Full Range 816 to 1910 | hr*ng/mL | |
| Total Area Under the Plasma Concentration Curve of Entinostat: AUC | PK Part With 4 mg/m² | 1147 | Full Range 1074 to 2349 | hr*ng/mL | |
| Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | Stratum 1 With 3 mg/m² | 1.01 | Full Range 0.53 to 6.00 | Hours | |
| Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | Stratum 1 With 4 mg/m² | 0.59 | Full Range 0.50 to 24.55 | Hours | |
| Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | PK Part With 4 mg/m² | 1 | Full Range 0.50 to 24.08 | Hours | |
| Antitumor Activity of Entinostat | Stratum 1 With 3 mg/m² | 0 | Participants | ||
| Antitumor Activity of Entinostat | Stratum 1 With 4 mg/m² | 0 | Participants | ||
| Antitumor Activity of Entinostat | PK Part With 4 mg/m² | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02780804/results